CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS

  01 July 2020

CARB-X announced that it is awarding up to US$1.82 million to Eligo Bioscience in Paris, France, with additional funding for a total award of up to US$7.05 million if project milestones are met, for the development of a new generation of highly-specific antimicrobials to prevent multi-drug-resistant bacterial infections in organ transplant patients. Eligo’s bacteriophage- and CRISPR-based therapeutics are designed to selectively eliminate extended-spectrum beta-lactamase-producing (ESBL) and Carbapenem-resistant E. coli and K. Pneumoniae (CRE) from the microbiome of transplant patients before their procedure, thereby preventing the onset of these often-fatal infections.

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back


Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market
  • Global reach for funding / co-development / licensing
Display your technology and make use of the Continuous AMR Partnering Initiative >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!